Immune Checkpoint Inhibitor Toxicity Risk Prediction in Solid Tumors
This study examines how certain risk factors (such as age, gender, other medical conditions, and the type of immunotherapy used to treat the cancer) affect whether a patient with a malignant solid tumor will develop mild or serious side effects from the immunotherapy medications. Immunotherapy is the type of treatment that helps the body's immune system fight cancer. In the future, this information may help doctors make better decisions about cancer treatments.
Research Base: SWOG Cancer Research Network
NCT ID: NCT04871542
NCI Protocol Number: SWOG-S2013
Status: Recruiting
For more information see ClinicalTrials.gov
Interventions
- Biospecimen Collection
- Questionnaire Administration
Condition
Malignant Solid Neoplasm
Trial Type
Other
See a list of participating sites on ClinicalTrials.gov